Wiley Handbook of Current and Emerging Drug Therapies, Volumes 1-4
点此进入淘宝搜索页搜索分類: 图书,进口原版,Medicine（医学）,Internal Medicine（内科医学）,
品牌: John Wiley & Sons Ltd
基本信息出版社:Wiley-Interscience; 1 (2006年12月11日)精装:2664页正文语种:英语ISBN:047004098X条形码:9780470040980商品尺寸:17.6 x 19 x 25.5 cm商品重量:5 KgASIN:047004098X商品描述内容简介Here is an all-encompassing reference tailored to the needs of research managers, chemists and biologists, clinical scientists, and executives in the pharmacology and biotechnology industry. No other resource focuses on drug discovery and pharmaceutical research from this unique perspective combining scientific and business aspects of today's biotechnology.Within every major therapeutic area, the Wiley Handbook of Current and Emerging Drug Therapies provides a general overview of the etiology and pathophsiology of the important disease indications. Then, you'll find a comprehensive analysis of currently approved drugs targeting these diseases, with information on mechanism of action, efficacy, side effects and future prospects. You'll also find product-by-product analyses of drugs currently in development, including mechanism of action, formulations, and detailed information on the status of clinical trials.This reference also includes authoritative essays on key topics:The Drug Discovery Process—Overview
[Dr. Hugo Kubinyi of the University of Heidelberg]Clinical Trials—Overview
[Dr. Curtis L. Meinert, Director of the Johns Hopkins Center for Clinical Trials]and detailed, market-oriented analyses of:Emerging Technologies and Business OpportunitiesGlobal Markets and National PolicyNew Opportunities in Drug Discovery and Pipeline DevelopmentAlso available in a regularly-updating online version. Visit www.interscience.wiley.com/mrw/cedt for more information.目录PART I: INTRODUCTION.
The Drug Discovery Process.
Clinical Trials, Overview.
Therapeutic Area Trends in R&D of the Top 20 Pharmaceutical Companies.
PART II: ONCOLOGY.
Aggressive Non-Hodgkin's Lymphomas.
Bladder Cancer.
Breast Cancer.
Cervical Cancer.
Chronic Lymphocytic Leukemia (CLL).
Chronic Myelogenous Leukemia.
Colorectal Cancer.
Malignant Melanoma.
Multiple Myeloma.
Cumulative Index of Drug and Molecule Names, Volumes 1-4.
Subject Index.
Volume 2.
PART II: ONCOLOGY.
Non-Small-Cell Lung Cancer.
Ovarian Cancer.
Pancreatic Cancer.
Prostate Cancer.
Small-Cell Lung Cancer.
PART III: IMMUNE SYSTEM.
Allergic Rhinitis.
Asthma.
Crohn's Disease.
Psoriasis.
Rheumatoid Arthritis.
Cumulative Index of Drug and Molecule Names, Volumes 1-4.
Subject Index.
Volume 3.
PART IV. METABOLIC DISEASES.
Diabetic Retinopathy.
Dyslipidemia.
Metabolic Syndrome.
Obesity.
Osteoporosis.
Type 1 Diabetes.
Type 2 Diabetes.
PART V. INFECTIOUS DISEASES.
Acute Exacerbations of Chronic Bronchitis.
Community-Acquired Pneumonia.
Complicated Skin and Soft Tissue Infections.
Hepatitis C.
Methicillin-Resistant Staphylococcus Aureus.
Cumulative Index of Drug and Molecule Names, Volumes 1-4.
Subject Index.
Volume 4.
PART VI. EMERGING TECHNOLOGIES AND BUSINESS OPPORTUNITIES.
Data and Information Integration in Pharmaceutical R&D.
Impact of Technological Advances on Pharmaceutical Productivity.
Advances in Medicinal Chemistry and Lead Optimization.
Bio-Defense Opportunities in the Biotechnology and Pharmaceutical Industries.
Fear of Theranostics: Why an Industry Has Not Really Emerged.
Beyond Commodity Drugs: Strategic Diversification in the Generics Industry.
PART VII: GLOBAL MARKETS AND NATIONAL POLICY.
The EU Clinical Trials Directive: Impact in Europe and Beyond.
The Indian Pharmaceutical Industry in Transition: Changes and Opportunities Ahead.
Spotlight on the Australian and New Zealand Pharmaceutical and Biotechnology Industries.
Overview of the World's Major OTC Markets.
Biotech Hubs-Key Growth Engines for Drug Development.
Pharmaceutical Marketplace in Central and Eastern Europe.
Valuation Models for European Biotech.
Taking Global Action: Integrating Social Responsibility into Corporate Practices.
Global Branding Strategy: From the Blockbuster to the Targeted Model.
PART VIII: NEW OPPORTUNITIES IN DRUG DISCOVERY AND PIPELINE DEVELOPMENT.
Prospects for Genomics-Derived Drugs: New Approaches and Impact on Pharmaceutical Pipelines.
Prying Open the Pipeline: Drug Discovery and Development in the Postgenomics Era.
Glycomics: The Impact of Carbohydrates on Biological Function and the Implications for Drug Discovery.
High-Content Screening for Drug Discovery and Target Validation.
High-Throughput ADMET Screening: Improving the Efficiency of Drug Discovery.
Emerging Concepts in GPCR Research and Their Implications for Drug Discovery.
Optimizing Knowledge Management in Pharmaceutical Companies.
Cumulative Index of Drug and Molecule Names, Volumes 1-4.
Subject Index.
Cumulative Subject Index, Volumes 1-4.
